Please answer all questions
1. What can mutation lead trastuzumab resistance with lapatinib sensitivy from HER2+ cancers.
2. What can another oncogeneic mutation be which lets HER2+ tumors being positive, have resistance to the lapatanib.
*NOTE: Kindly repost for other question. Dear Student as per the guidelines we are supposed to answer only one of the question. So please repost the question for getting the answers for others too thank you.
1.Lapatanib is a HER2 kinase inhibitor and it is used for people with over breast cancer who will have HER2 kinase in excessive as it will inhibit the HER2 kinase it is given to people with over breast cancer.
* JIMT-1 and MDA453 are the cells which possess PIK3CA mutation that is resistance to trastuzumab also reduced sensitivity to lapatinib.
*So these mutations will cause sensitivity to lapatinib these will make it to sensitive to HER2+ cancers .
Trending now
This is a popular solution!
Step by step
Solved in 2 steps
